The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2
eLife · 04.02.2025 · 13
DOI: 10.7554/elife.97577 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 04.02.2025. Verfasst von Adam D Longhurst und 14 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco, San Francisco, United States. Hauptthemen laut MEDLINE: Cyclin D1, Cyclin D2, Polycomb Repressive Complex 2, G1 Phase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NEI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Progression through the G1 phase of the cell cycle is the most highly regulated step in cellular division. We employed a chemogenetic approach to discover novel cellular networks that regulate cell cycle progression. This approach uncovered functional clusters of genes that altered sensitivity of cells to inhibitors of the G1/S transition. Mutation of components of the Polycomb Repressor Complex 2 rescued proliferation inhibition caused by the CDK4/6 inhibitor palbociclib, but not to inhibitors of S phase or mitosis. In addition to its core catalytic subunits, mutation of the PRC2.1 accessory protein MTF2, but not the PRC2.2 protein JARID2, rendered cells resistant to palbociclib treatment. We found that PRC2.1 (MTF2), but not PRC2.2 (JARID2), was critical for promoting H3K27me3 deposition at CpG islands genome-wide and in promoters. This included the CpG islands in the promoter of the CDK4/6 cyclins CCND1 and CCND2, and loss of MTF2 lead to upregulation of both CCND1 and CCND2. Our results demonstrate a role for PRC2.1, but not PRC2.2, in antagonizing G1 progression in a diversity of cell linages, including chronic myeloid leukemia (CML), breast cancer, and immortalized cell lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California, San Francisco, San Francisco, United States.
- Tetrad Graduate Program, University of California, San Francisco, San Francisco, United States.
- Department of Molecular Genetics, University of Toronto, Toronto, Canada.
- The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.
- Gladstone Institute for Data Science and Biotechnology, J. David Gladstone Institutes, San Francisco, United States.
- Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States.
ORCID-Profile: Adam D Longhurst, Brenda J Andrews, David P Toczyski
Förderung
- NIA NIH HHS
- NEI NIH HHS
- NIGMS NIH HHS
- NIDA NIH HHS
- Sandler Program for Breakthroughs in Biomedical Research (PBBR)
- NHGRI NIH HHS
- NIH Office of the Director
Zitieren
APA
Longhurst, A. D., Wang, K., Suresh, H. G., Ketavarapu, M., Ward, H. N., Jones, I. R., Narayan, V., Hundley, F. V., Hassan, A. Z., Boone, C., Myers, C. L., Shen, Y., Ramani, V., Andrews, B. J., & Toczyski, D. P. (2025). The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2. eLife, 13. https://doi.org/10.7554/elife.97577
Vancouver
Longhurst AD, Wang K, Suresh HG, Ketavarapu M, Ward HN, Jones IR, et al. The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2. eLife. 2025;13. doi:10.7554/elife.97577
BibTeX
@article{Longhurst2025,
author = {Longhurst, Adam D and Wang, Kyle and Suresh, Harsha Garadi and Ketavarapu, Mythili and Ward, Henry N and Jones, Ian R and Narayan, Vivek and Hundley, Frances V and Hassan, Arshia Zernab and Boone, Charles and Myers, Chad L and Shen, Yin and Ramani, Vijay and Andrews, Brenda J and Toczyski, David P},
title = {The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2},
journal = {eLife},
year = {2025},
volume = {13},
doi = {10.7554/elife.97577}
}
EUVIMED